Addex Partner Completes ADX71149 Phase I Program
(Thomson Reuters ONE) -
Addex Pharmaceuticals / Addex Partner Completes ADX71149 Phase I Program processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
Geneva, Switzerland, 25 August 2010 - Allosteric modulation company Addex
Pharmaceuticals Ltd (SIX:ADXN) announced today that the Phase I studies required
to commence Phase II testing of ADX71149 have been satisfactorily completed.
Subject to regulatory authorizations, Phase IIa studies in schizophrenia and
anxiety, are scheduled to start enrolling patients in the first quarter of 2011.
The Phase I program was conducted by Johnson & Johnson Pharmaceutical Research
and Development (J&JPRD) on behalf of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
(OMJPI) and included more than five studies in normal human volunteers,
including: single ascending dose; multiple ascending dose; food & gender;
ketamine challenge (a model of psychosis); and anxiety challenge.
In 2005, Addex Pharmaceuticals announced it had entered an exclusive worldwide
research collaboration and license agreement with OMJPI to discover, develop and
commercialize novel allosteric compounds for the treatment of anxiety,
depression, schizophrenia and Alzheimer's disease. The initial drug discovery
research was conducted both at Addex and at J&JPRD. Under the terms of the
agreement, OMJPI paid Addex a ?3 million upfront fee and research funding for 2
years. In addition, Addex is eligible for up to a total of ?112 million subject
to successful completion of development and regulatory milestones. In addition,
Addex is eligible for low double-digit royalties on sales of ADX71149, subject
to regulatory approval and successful commercial launch.
"ADX71149 is a truly innovative, potentially life changing drug candidate for
patients suffering from schizophrenia, anxiety and possibly other disorders,"
CEO Vincent Mutel said. "The Phase I program demonstrates that ADX71149
tolerability and safety monitoring parameters were within acceptable limits and
support continued study in patients."
ADX71149 is an mGluR2 positive allosteric modulator (PAM) being developed by
OMJPI. Activation of mGluR2 is a clinically validated mechanism in both
schizophrenia and anxiety.
Addex Pharmaceuticals (www.addexpharma.com) discovers and develops allosteric
modulators for human health and is focused on validated therapeutic targets for
diseases of the central nervous system, metabolic disorders and inflammation.
Subject to regulatory approvals, Phase II clinical trials are expected to start
soon in four indications for two lead products: ADX48621, an mGluR5 negative
allosteric modulator (NAM), in dystonia and Parkinson's disease levodopa-induced
dyskinesia (PD-LID); and ADX71149, an mGluR2 positive allosteric modulator
(PAM), in schizophrenia and anxiety. A third product, ADX71943, GABA-B receptor
PAM with potential for chronic pain, is scheduled to enter Phase I testing in
2011. In addition, Merck & Co., Inc. has licensed rights to two preclinical
products: mGluR4 PAM for Parkinson's disease and mGluR5 PAM for schizophrenia.
Additional preclinical discovery stage programs include: mGluR2 NAM, GLP1R PAM,
IL1R1 NAM and TNFR1 NAM. Roche Venture Fund and SR-One, corporate venture arm of
GlaxoSmithKline, are investors in Addex.
Chris Maggos
Investor Relations & Communications
Addex Pharmaceuticals
+41 22 884 15 11
chris.maggos(at)addexpharma.com
Disclaimer: The foregoing release may contain forward-looking statements that
can be identified by terminology such as "not approvable", "continue",
"believes", "believe", "will", "remained open to exploring", "would", "could",
or similar expressions, or by express or implied discussions regarding Addex
Pharmaceuticals Ltd, its business, the potential approval of its products by
regulatory authorities, or regarding potential future revenues from such
products. Such forward-looking statements reflect the current views of Addex
Pharmaceuticals Ltd regarding future events, future economic performance or
prospects, and, by their very nature, involve inherent risks and uncertainties,
both general and specific, whether known or unknown, and/or any other factor
that may materially differ from the plans, objectives, expectations, estimates
and intentions expressed or implied in such forward-looking statements. Such may
in particular cause actual results with allosteric modulators of mGluR2, mGluR4,
mGluR5, mGluR7 or other therapeutic targets to be materially different from any
future results, performance or achievements expressed or implied by such
statements. There can be no guarantee that allosteric modulators of mGluR2,
mGluR4, mGluR5, mGluR7 will be approved for sale in any market or by any
regulatory authority. Nor can there be any guarantee that allosteric modulators
of mGluR2, mGluR4, mGluR5, mGluR7 or other therapeutic targets will achieve any
particular levels of revenue (if any) in the future. In particular, management's
expectations regarding allosteric modulators of mGluR2, mGluR4, mGluR5, mGluR7
or other therapeutic targets could be affected by, among other things,
unexpected actions by our partners, unexpected regulatory actions or delays or
government regulation generally; unexpected clinical trial results, including
unexpected new clinical data and unexpected additional analysis of existing
clinical data; competition in general; government, industry and general public
pricing pressures; the company's ability to obtain or maintain patent or other
proprietary intellectual property protection. Should one or more of these risks
or uncertainties materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those anticipated, believed, estimated
or expected. Addex Pharmaceuticals Ltd is providing the information in this
press release as of this date and does not undertake any obligation to update
any forward-looking statements contained in this press release as a result of
new information, future events or otherwise, except as may be required by
applicable laws.
[HUG#1439952]
--- End of Message ---
Addex Pharmaceuticals
12, chemin des Aulx Plan-les-Ouates; Geneva Switzerland
ISIN: CH0029850754;
Français (pdf):
http://hugin.info/138017/R/1439952/384299.pdf
Deutsch (pdf):
http://hugin.info/138017/R/1439952/384399.pdf
English (pdf):
http://hugin.info/138017/R/1439952/384312.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
All reproduction for further distribution is prohibited.
Source: Addex Pharmaceuticals via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 25.08.2010 - 07:00 Uhr
Sprache: Deutsch
News-ID 39963
Anzahl Zeichen: 0
contact information:
Town:
Plan-les-Ouates, Geneva
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 227 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Addex Partner Completes ADX71149 Phase I Program"
steht unter der journalistisch-redaktionellen Verantwortung von
Addex Pharmaceuticals (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
